Form 8-K

8-K — Neuphoria Therapeutics Inc.

Accession: 0001213900-26-061028

Filed: 2026-05-26

Period: 2026-05-21

CIK: 0001191070

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Documents

8-K — ea0292160-8k_neuphoria.htm (Primary)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0292160-8k_neuphoria.htm · Sequence: 1

false

0001191070

2026-05-21

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

United

States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT

REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date

of Report (date of earliest event reported): May 21, 2026

Neuphoria Therapeutics Inc.

(Exact

name of Registrant as Specified in its Charter)

Delaware

(State

Or Other Jurisdiction of Incorporation)

001-41157

99-3845449

(Commission

File Number)

(I.R.S.

Employer Identification No.)

100 Summit Dr, Burlington, Massachusetts

01803

(Address

of Principal Executive Offices)

(Zip

Code)

(781) 439-5551

Registrant’s

Telephone Number, Including Area Code

Securities

registered pursuant to Section 12(b) of the Act:

Title

of Each Class

Trading

Symbol

Name

of each exchange on which registered

Common Stock, $0.00001 par value per share

NEUP

The

Nasdaq Stock Market, LLC

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

8.01 Other Events

May 21, 2026, Neuphoria Therapeutics Inc. (the “Company”) received a revenue distribution payment of AUD $1.416M from

its participation in the former Cancer Therapeutics Cooperative Research Centre (CTx CRC) related to the Company’s licensing of

the KAT6 program to Pfizer Inc. following the initiation of dosing of the first subject in the first Phase III Clinical Trial in ER+/HER2-

metastatic breast cancer. Based on past program contributions, Neuphoria believes it is eligible to receive approximately 4.65% of future

milestone payments, if any, from CTXT, of which the total value to all 17 parties (see below) combined is estimated to be USD$460M. As

a passive party, the Company is not able to determine whether future milestones will be achieved, whether the Company will receive any

future milestone payments, or the size of any such payments, if received.

CTx

CRC was founded in 2007, received an initial seven years of funding from the Cooperative Research Centre (CRC) Programme and was then

awarded a further six years of CRC Programme funding beginning in July 2014. The CTx CRC concluded in December 2020 and evolved into

a private company -- Canthera Discovery. In addition to the CRC Programme funding, CTx CRC received licensing revenues and additional

cash and in-kind funding from its 17 partners, one of which was Bionomics Ltd. (now known as Neuphoria Therapeutics Inc.).

CTx

CRC engaged in research targeted at the treatment of various cancers. It out-licensed multiple oncology programs and established itself

as a leader in epigenetics and immuno-oncology. CTx CRC commercialized multiple drug discovery projects on behalf of its 17 partners,

including with leading pharmaceutical companies, MSD and Pfizer.

one of the 17 partners, in addition to the Cancer Research Council and Wellcome Trust, the Company has received revenue from its successful

participation in the CTx CRC, and believes it may continue to benefit from future milestone payments and royalties as licensed programmes

from the CTx CRC continue to be developed.

Revenues

to date have included:

● In

2016, AUD $967,583 in licensing funds as part of an agreement between MSD and the CTx CRC

following an initial payment of USD15 million to the CTx CRC for PRMT5

● In

2018, AUD $654,149 in licensing revenue following the CTx CRC license of two targets to Pfizer.

● In

2020, AUD $46,662 from the Company’s participation in the CTx CRC and CTx CRC’s

licensing of two targets to Pfizer.

● In

2021, AUD $263,634 from the Company’s participation in the CTx CRC and CTx CRC’s

licensing of two targets to Pfizer.

● In

2022, AUD $22,047 from the Company’s participation in the CTx CRC and CTx CRC’s

licensing of two targets (FAK and PRMT5).

● In

2023, AUD $8,295 from the Company’s participation in the CTx CRC and CTx CRC’s

licensing of two targets (FAK and PRMT5).

● In

2024, AUD $23,717 from the Company’s participation in the CTx CRC and CTx CRC’s

licensing of a target (PRMT5).

● In

2026, AUD $120,298 from the Company’s participation in the CTx CRC and CTx CRC’s

licensing of a target (FAK).

● In

2026, AUD $1,416,026 from the Company’s participation in the CTx CRC and CTx CRC’s

licensing of two targets to Pfizer.

The

CRC trusts have made total distributions to the Company to date of AUD $3,522,413.68 since 2016.

Forward-Looking

Statements

This

Current Report on Form 8-K includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements

that are not historical facts within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities

Exchange Act of 1934, as amended. We may in some cases use terms such as “predicts,” “believes,” “potential,”

“continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,”

“may,” “could,” “might,” “likely,” “will,” “should” or other

words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Such forward-looking statements

are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Readers are cautioned

not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company expressly disclaims

any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect

any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any

statement is based. Any or all of the forward-looking statements may turn out to be wrong or be affected by assumptions we make that

later turn out to be incorrect, or by known or unknown risks and uncertainties. For all these reasons, actual results and developments

could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue

reliance on these forward-looking statements, which are made only as of the date of this Current Report on Form 8-K. We undertake no

obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances unless required by law.

SIGNATUREs

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned, thereunto duly authorized.

NEUPHORIA

THERAPEUTICS INC.

By:

/s/

Spyridon Papapetropoulos

Chief Executive Officer

Date: May 26, 2026

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Cover

May 21, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 21, 2026

Entity File Number

001-41157

Entity Registrant Name

Neuphoria Therapeutics Inc.

Entity Central Index Key

0001191070

Entity Tax Identification Number

99-3845449

Entity Incorporation, State or Country Code

Entity Address, Address Line One

100 Summit Dr

Entity Address, City or Town

Burlington

Entity Address, State or Province

Entity Address, Postal Zip Code

01803

City Area Code

781

Local Phone Number

439-5551

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.00001 par value per share

Trading Symbol

NEUP

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration